Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD985 in HER2-Expressing Endometrial Carcinoma
NCT04205630Phase 2Completed
- Sponsor
- Byondis
- Start
- May 2020
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab duocarmazine in endometrial cancer (EC), sponsored by Byondis. Primary endpoint: Objective Response Rate at 2 years. Started May 2020; status: completed.
02
Drugs
trastuzumab duocarmazine
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04205630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205630.